Abstract: A process for producing zinc toluenesulfonate comprising reacting a zinc compound comprising Zn(OH)2 with toluenesulfonic acid and/or a salt thereof in the presence of an alcohol having 1 to 20 carbon atoms in total at a temperature higher than 60° C.

Abstract: The invention is directed to a method of treating fibromyalgia syndrome in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.

Abstract: The invention provides compounds containing the ring-opening products of ethylenically unsaturated cyclic carbonates for use in preparing hydrogel polymers, as well as methods for their preparation. A preferred method of the invention includes the reaction of nucleophilic compounds containing Si, F, N or O atoms, or combinations thereof, or latent moieties in the form of unsaturated or hydroxylated functional groups, with ethylenically unsaturated glycerol carbonate derivatives. The compounds and hydrogel polymers are useful for the preparation of contact lenses.

Abstract: Novel crosslink agents are described that provide for the copolymerization of at least one hydrophilic monomer with at least one lens monomer typically used to prepare materials for ophthalmic lenses. The new crosslink agents have a relatively high selectivity for the hydrophilic monomer and limited reactivity with the crosslink agent used to polymerize the lens monomer.

Abstract: This disclosure relates to methods for preparing an enantiomerically enriched N-carboxyanhydride of an amino alpha acid of the formula (IIIa) or (IIIb): from a compound of the formula (IIa) or (IIb), respectively: wherein R1, R2, and R3 are as defined in the disclosure.

Abstract: The invention is directed to a method of treating addiction to drugs of abuse in a subject, comprising administering a therapeutically effective amount of a cabamoyl compound, or pharmaceutically acceptable salt or ester thereof.

Abstract: The present invention is directed to triclosan derivatives and nanoparticles comprising said derivatives together with an organic or an inorganic carrier. The present invention is also directed to uses of the triclosan nanoparticles for preventing or inhibiting bacterial growth.

Abstract: The present invention relates to GABA-linked anthracycline-lipid conjugates and to methods of using the conjugates to treat cancer. Methods for making the GABA-linked anthracycline lipid conjugates are also provided.

Abstract: A radiation-sensitive resin composition includes a compound, a resin and a radiation-sensitive acid generator. The compound has a structure in which a group represented by a following formula (1) is bound to a nitrogen atom. The resin has an acid-dissociative dissolution-controlling group and has a property such that alkali solubility of the resin increases by an action of an acid. In the formula (1), Y is a monovalent group having 5 to 20 carbon atoms, and “*” represents a bonding hand with the nitrogen atom. In the formula (i), R1, R2 and R3 each independently represent a linear or branched alkyl group having 1 to 4 carbon atoms or a monovalent alicyclic hydrocarbon group having 4 to 12 carbon atoms, or R1 and R2 are linked with each other to form a bivalent alicyclic hydrocarbon group, and “*” represents a bonding hand with the oxygen atom.

Abstract: The present invention is aimed to provide a method for industrially producing a useful substance (protein etc.) utilizing a bacterium such as Escherichia coli in the presence of a surfactant and a surfactant to be used in this method for producing a useful substance. The present invention is a method for producing a useful substance into a culture solution by secretion by a bacterium in the culture solution, wherein the culture solution contains a surfactant (A), and a dried cell density based on the volume of the culture solution is 1.5 to 500 g/L. More preferably, the present invention is a method for producing a useful substance wherein the surfactant (A) is at least one agent selected from the group consisting of an amphoteric surfactant, an anionic surfactant, and a nonionic surfactant having an HLB value of 0 to 13.

Abstract: Methods to convert biobased oils, oil derivatives, and modified oils to highly functionalized esters, ester polyols, amides, and amide polyols. The products can be used to make polyurethane and polyester films and foams.

Abstract: A (?)-stereoisomer of formula (I): (formula I), wherein X is H or F; or a pharmaceutically acceptable salt or prodrug thereof, is useful as an anesthetic.

Abstract: A composition comprising at least one curable compound (I) advantageously having a refractive index Formula (I) of at least 1.60 and obtained from the reaction of A at least one aromatic polyisocyanate, B at least one monofunctional alcohol or amine, C at least one further monofunctional alcohol or amine different from B, D at least one diol or diamine, and E optionally a hydroxyl group containing (meth)acrylate, the compound (I) comprising at least one curable functional group selected from the group consisting of carbon-carbon double bonds and epoxy groups.

Abstract: The invention relates to the production of carbamates in a single reactor (one-pot) using solid catalysts, involving the reaction between at least one nitro compound, an organic carbonate of formula (OR)(OR?)C?O, a gas selected from hydrogen gas and a mixture of gases containing hydrogen and hydrogen precursor compounds, and a catalyst that has at least one metallic oxide and can also contain an element of groups 8, 9, 10 and 11 of the periodical table. The carbonates obtained can be transformed into their corresponding isocyanates.

Abstract: The present invention relates to new, urethane-group-containing polyisocyanates based on aliphatic and/or cycloaliphatic diisocyanates, and to their use.

Abstract: Reaction products prepared from reactants including: (a) at least one compound of structural Formula (I): wherein R1 is selected from aryl and heteroaryl; X is selected from a direct bond, —O—, —S—, —NH—, alkylene, cycloalkylene, heterocyclylene, arylene, alkarylene, and heteroarylene; Y is a substituted alkylene group having at least two contiguous carbon atoms and which can be interrupted by one or more —O—, —S—, or —NH— moieties as defined herein, wherein the alkylene group of Y has substituents independently selected from —OH, —NH2, —SH, cycloalkyl, heterocyclyl, aryl, and heteroaryl, or two hydrogen atoms on the same carbon atom of Y are replaced by carbonyl, and wherein at least two substituents of Y are each independently selected from —OH, —NH2, and —SH, as defined herein; and (b) at least one isocyanate functional material.

Abstract: Methods for synthesis of 1-(acyloxy)-alkyl carbamates, particularly, the synthesis of 1-(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1-(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.

Abstract: (A1) Translate this text The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.

Abstract: The present invention generally relates to methods for performing metathesis reactions, including cross-metathesis reactions. Methods described herein exhibit enhanced activity and stereoselectivity, relative to known methods, and are useful in the synthesis of a large assortment of biologically and therapeutically significant agents.

Abstract: The present invention provides a urethane-forming reaction catalyst which is useful for catalyzing a reaction between an isocyanate compound, in particular, an aliphatic isocyanate and a hydroxyl group-containing compound to form a urethane material, which does not affect the performance of the urethane material, and which can be easily removed from the resulting urethane material, and a method for producing a metal compound-free urethane material using the urethane-forming reaction catalyst. The catalyst of the present invention is a urethane-forming reaction catalyst for producing a urethane material by allowing a hydroxyl group-containing compound to react with an isocyanate compound, the catalyst being at least one solid acid catalyst selected from the group consisting of a (A) composite metal oxide in which a metal oxide (A-2) or a non-metal compound (A-3) is carried on a surface of a metal oxide carrier (A-1), (B) zeolite, and a (C) heteropoly acid.

Abstract: A crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug and methods of preparing a crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug, and methods of using a crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug are provided.

Abstract: Methods to convert biobased oils, oil derivatives, and modified oils to highly functionalized esters, ester polyols, amides, and amide polyols. The products can be used to make polyurethane and polyester films and foams.

Abstract: An object of the present invention is to provide a novel photobase generator which can sensitively generate a base even by h-ray in place of a conventional 2-nitro-4,5-dimethoxybenzyloxycarbonylamine compound. Disclosed is an N-(?-aromatic group-substituted-2-nitro-4,5-dialkoxybenzyloxycarbonyl)amine compound represented by the following general formula (I). (In the above formula (I), R1 to R9 denote specific groups.

Abstract: The present invention pertains to a catalyst for the synthesis of organic alkyl carbamates, the method for preparing the same and the use thereof. The catalyst comprises a catalytically active component and a catalyst support, and the catalytically active component being carried by the catalyst support, wherein the catalytically active component comprises a transition metal oxide, and the general formula of the transition metal oxide is EOx, wherein E is selected from transition metal element and x is in the range of 0.5-4.

Abstract: The invention provides certain bis-acylated hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invention provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or develop of a disease or condition. In some embodiments, the disease or condition is selected from cardiovascular diseases, ischemia, reperfusion injury, cancerous disease, pulmonary hypertension and conditions responsive to nitroxyl therapy.

Abstract: There is provided an amino acid generator comprising a protecting group for an amino group that is eliminated to generate an amino acid, and a coating film forming composition using the amino acid generator and a polysiloxane composition containing the amino acid generator. A coating film forming composition comprising: a component (A): an amino acid generator comprising a protecting group that is eliminated to generate an amino acid, which is a compound of Formula (1): D-A (1) where D is a protecting group for an amino group, and A is an organic group remaining after subtracting hydrogen atoms from an amino group of an amino acid; a component (B): a hydrolyzable silane, a hydrolysis product thereof, a hydrolysis-condensation product thereof, or a mixture thereof; and a component (C): a solvent.

Abstract: Oligomeric reagents are provided comprising a moiety of atoms arranged in a specific order, wherein the moiety is positioned between a water-soluble, non-peptidic oligomer and a pharmaceutically active agent. The oligomeric reagents are useful for, among other things, forming oligomer active agent conjugates. Related methods, compositions, preparations, and so forth are also provided.

Abstract: The present invention provides a photoresist composition comprising a resin, an acid generator and a compound represented by the formula (I): wherein R1, R2 and R3 each independently represent a hydrogen atom or a C1-C4 alkyl group, A1 represents a single bond or a C1-C2 alkylene group, R4 and R5 each independently represent a hydrogen atom or a C1-C2 alkyl group, R6 and R7 each independently represent a hydrogen atom etc.

Abstract: Carbamoyl esters inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. In one embodiment, the carbamoyl ester has the following structure: wherein A is selected from the group consisting of an unsubstituted aryl, a substituted aryl, an unsubstituted heteroaryl and a substituted heteroaryl. The carbamoyl esters are employed in methods to treat an individual. The pharmacologically active agent obtained by hydrolysis of the carbamoyl esters can treat, for example, a nervous system condition, a cholinergic deficiency and conditions or diseases associated with a deficiency in a pharmacologically active agent, such as acetylcholine.

Abstract: The present invention provides a compound represented by the formula (C1): wherein Rc2 represents a C6-C10 aromatic hydrocarbon group having at least one nitro group and Rc1 represents a group represented by the formula (1): wherein Rc4 represents a hydrogen atom etc., Rc5 represents a C1-C30 divalent hydrocarbon group, and Rc3 represents a group represented by the formula (3-1), (3-2) or (3-3): wherein Rc6, Rc7, Rc8, Rc9, Rc10, Rc11, Rc12, Rc13 and Rc14 each independently represent a C1-C30 hydrocarbon group, and a photoresist composition comprising a resin, an acid generator and the compound represented by the formula (C1).

Abstract: A prepolymer and products made from the preopolymer is described. The prepolymer includes the reaction product of at least one isocyanate and at least one natural oil based polyol. The natural oil based polyol includes at least two natural oil moieties separated by a molecular structure having an average of at least about 19 ether groups between any 2 of the natural oil moieties or by a polyether molecular structure having an equivalent weight of at least about 480.

Abstract: The present invention relates to a polymerization-curable composition for the preparation of biodegradable, biocompatible, cross-linked polymers on the basis of polyvinyl alcohol comprising: 5 to 100% by weight of (a) vinyl ester monomer(s) of one of the general formulas (I) to (III): wherein X is oxygen, sulfur, nitrogen, or phosphorus; n is 1 to 1000, at least 20% of the n being ?2; the R1 are selected from hydrogen; straight, branched or cyclic, saturated or unsaturated, n-valent hydrocarbon groups having 1 to 30 carbon atoms, which optionally have heteroatoms and are optionally substituted with one or more substituents selected from —OH, —COON, —CN, —CHO, and ?O, and n-valent radicals of biodegradable, biocompatible oligomers and polymers; m is an integer from 1 to 5; the R2 are selected from hydrogen, —OH, ?O, and the options listed for R1; and the R3 are selected from hydrogen, —OH, and the options listed for R1; 0 to 50% by weight of ethylenically unsaturated co-monomers; 0 to 10% by weight of (a)

Abstract: A urea-urethane compound having one or more urea groups and one or more urethane groups in the molecular structure, the number of said urea groups (A) and the number of said urethane groups (B) satisfying the following numerical formula: 10?(A+B)?3 wherein each of A and B is an integer of 1 or more.

Abstract: The ring-containing modified resin is represented by the following chemical formula (1) R1[—(—O—CO—NH—R2—NH—CO—O—R3—)p—O—R4]q??(1) (in the chemical formula (1), R1 is a dehydroxyl residue of a resin having a benzene ring and/or a condensed ring and hydroxyl group: —R2— is deisocyanate group derived from an organic diisocyanate: —R3— is a dehydroxyl residue of polyol having number-average molecular weight of 200 to 30000: p is 1 to 3: —R4 is a hydrogen atom, alkyl group having 1 to 18 carbons, phenyl group: q is the same number as the number of the dehydroxyl residue of R1).

Abstract: Process for the synthesis of non cyclic carbamate derivatives from amine compounds, alcohols and CO2 in the presence of ionic liquids and optionally in the presence of a base.

Abstract: A novel use of conjugates of psychotropic drugs (e.g., antidepressants or anti-epileptic drugs) and organic acids such as GABA in the treatment of pain is disclosed. A novel GABA conjugate and uses thereof is also disclosed.

Abstract: The present invention provides methods of forming carbamates, ureas, and isocyanates. In certain embodiments these methods include the step of reacting an amine with an ester-substituted diaryl carbonate to form an activated carbamate which can be further derivitized to form non-activated carbamate or a urea. The urea or carbamate can be subjected to a pyrolysis reaction to form isocyanate.

Abstract: The present invention relates to carbamoylation of amines, mercaptanes, thiophenols and phenols employing organic azides. More specifically, the invention relates to a method for generating urea derivatives, thiocarbamate derivatives and carbamate derivatives, and is based on the intermediate formation of isocyanate, starting from an organic azide. The reaction as described is useful in applications for modified nucleoside synthesis, oligonucleotide synthesis, as well as modification, labeling and conjugation of polymers and biomolecules.

Abstract: The invention relates to a compound having general formula (I): Wherein n, A, R1, R2, and R3 are as defined herein. The invention also relates to methods of preparation of compound of formula (I) as well as its use in therapeutics.

Abstract: The present invention concerns geranylamine derivates of oxalic acid, use of the same as flavorings and certain mixtures, compositions, preparations and semi-finished goods containing one or more such compounds.

Abstract: The present invention includes a novel polyethylene glycol derivative; a drug carrier comprising the derivative; and a pharmaceutical composition comprising the drug carrier having a pharmacologically active substance included therein. Specifically disclosed are: a polyethylene glycol derivative represented by the general formula (I); a drug carrier comprising the derivative and 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoyl-glycerol; and a pharmaceutical composition comprising the drug carrier and a pharmacologically active substance (preferably double-stranded RNA, double-stranded DNA or an oligonucleic acid), wherein R represents a saturated or unsaturated aliphatic hydrocarbon group having 10 to 30 carbon atoms or a saturated or unsaturated fatty acid residue having 10 to 30 carbon atoms; and n represents an integer of 30 to 150.

Abstract: The invention relates to a compound of formula (I): Wherein m, n, X, Y, R1, R2, R3 and R4 are as defined herein. The invention also relates to the use of same in therapeutics.

Abstract: A compound, oligomer, or polymer having a functional group of formula (I) wherein R is a group having 1 to 12 carbons and optionally including one or more heteroatoms selected from oxygen, nitrogen, and sulfur is useful in curable compositions having active hydrogen functional groups reactive with group (I). The functional groups of formula (I) and active hydrogen functional groups may be part of the same material or different materials. In some embodiments a filler is surface modified to have a functional group of formula (I). Also disclosed is a method of making a material having a functional group of formula (I).

Abstract: Modified stable polyisocyanates are described having at least one isocyanate function modified by a group having cross-linking functionality.

Abstract: The present invention provides a novel method for preparing a key intermediate, 3-amino-pentan-1,5-diol (2), which is useful for the preparation of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)-propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidine-7-one (1) a MAP-kinase inhibitor useful in the treatment of rheumatoid arthritis.

Abstract: A urea-urethane compound having one or more urea groups and one or more urethane groups in the molecular structure, the number of said urea groups (A) and the number of said urethane groups (B) satisfying the following numerical formula: 10?(A+B)?3 wherein each of A and B is an integer of 1 or more.

Abstract: The present invention is directed to novel flame retardant monomers and polymers, wherein the flame retardant properties of the polymers are provided by functionality in pendant groups attached to a polymer backbone (as opposed to the polymer backbone itself possessing flame retardant properties. The present invention is also directed to methods of making such polymers and monomers, and articles of manufacture incorporating such monomers and polymers.

Abstract: This invention relates to a process for synthesizing Atazanvir, including novel intermediates and novel steps to various intermediates along the synthetic pathway.

Abstract: The invention provides a lipid of general formula (I) or (II): wherein X1, X2 and R1 to R5 are as defined herein. Such lipids are used to form complexes with a biologically-active material such as a nucleic acid, peptide or small molecule for delivering the biologically-active material to cells. The complexes may incorporate an integrin-binding peptide and, when the biologically-active material is DNA, thereby constitute a LID complex.

Abstract: Compounds of formula (I) wherein the groups are as defined in the description are disclosed. The compounds of formula (I) are endowed with reversible inhibiting activity of carnitine palmitoyl-transferase and are useful in the preparation of medicaments useful in the pathologies related to a hyperactivity of carnitine polymitoyl-transferase, such as hyperglycemia, diabetes and pathologies related thereto, heart failure, ischemia.